Therapeutic potential of klothoFGF23 fusion polypeptides: WO2009095372

Expert Opinion on Therapeutic Patents

Volumn 20, Issue 7, 2010, Pages 981-985

  Razzaque, Mohammed S ^a,b  

^a HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

^b The General Directorate of Armed Forces Health Services   (Saudi Arabia)

Author keywords

FGF23; Fusion polypeptides; Kidney; Klotho; Vitamin D

Indexed keywords

CALCITRIOL; HYBRID PROTEIN; KLOTHO FIBROBLAST GROWTH FACTOR 23 FUSION PROTEIN; OXYGENASE; PARATHYROID HORMONE; PHOSPHATE; POLYPEPTIDE; UNCLASSIFIED DRUG; VITAMIN D; BETA GLUCURONIDASE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 23; KLOTHO PROTEIN; PEPTIDE;

CHRONIC KIDNEY DISEASE; HOMEOSTASIS; HUMAN; IN VIVO STUDY; NONHUMAN; PATENT; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; TRANSGENIC MOUSE; ANIMAL; ARTICLE; CHEMISTRY; DRUG DELIVERY SYSTEM; METABOLISM; MOUSE;

ANIMALS; DRUG DELIVERY SYSTEMS; FIBROBLAST GROWTH FACTORS; GLUCURONIDASE; HUMANS; MICE; PARATHYROID HORMONE; PATENTS AS TOPIC; PEPTIDES; PHOSPHATES; VITAMIN D;

EID: 77953778295     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543771003774100     Document Type: Review

References (33)

1. Yamashita T, Yoshioka M, Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun 2000;277:494-498
2. ADHR-Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. The ADHR Consortium. Nat Genet 2000;26:345-348
3. Shimada T, Mizutani S, Muto T, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 2001;98:6500-6505
4. Goetz R, Nakada Y, Hu MC, et al. Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation. Proc Natl Acad Sci USA 2010;107:407-412
5. Medici D, Razzaque MS, Deluca S, et al. FGF-23-Klotho signaling stimulates proliferation and prevents vitamin D-induced apoptosis. J Cell Biol 2008;182:459-465
6. Jonsson KB, Zahradnik R, Larsson T, et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 2003;348:1656-1663
7. Benet-Pages A, Orlik P, Strom TM, Lorenz-Depiereux B. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet 2005;14:385-390
8. Fliser D, Kollerits B, Neyer U, et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007;18:2600-2608
9. Koh N, Fujimori T, Nishiguchi S, et al. Severely reduced production of klotho in human chronic renal failure kidney. Biochem Biophys Res Commun 2001;280:1015-1020
10. Chen CD, Podvin S, Gillespie E, et al. Insulin stimulates the cleavage and release of the extracellular domain of Klotho by ADAM10 and ADAM17. Proc Natl Acad Sci USA 2007;104:19796-19801
11. Kuro-o M, Matsumura Y, Aizawa H, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997;390:45-51
12. Nakatani T, Bara S, Ohnishi M, et al. In vivo genetic evidence of klotho-dependent functions of FGF23 in regulation of systemic phosphate homeostasis. Faseb J 2009;23:433-441
13. Razzaque MS, Lanske B. Hypervitaminosis D and premature aging: lessons learned from Fgf23 and Klotho mutant mice. Trends Mol Med 2006;12:298-305
14. Ohnishi M, Nakatani T, Lanske B, Razzaque MS. Reversal of mineral ion homeostasis and soft-tissue calcification of klotho knockout mice by deletion of vitamin D 1alpha-hydroxylase. Kidney Int 2009;75:1166-1172
15. Razzaque MS, Sitara D, Taguchi T, et al. Premature ageing-like phenotype in fibroblast growth factor 23 null mice is a vitamin-D mediated process. FASEB J 2006;20:720-722
16. Razzaque MS. The FGF23 Klotho axis: endocrine regulation of phosphate homeostasis. Nat Rev Endocrinol 2009;5:611-619
17. Razzaque MS. FGF23-mediated regulation of systemic phosphate homeostasis: Is Klotho an essential player? Am J Physiol Renal Physiol 2009;296:F470-6
18. Mohammadi M, Olsen SK, Ibrahimi OA. Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev 2005;16:107-137
19. Kurosu H, Ogawa Y, Miyoshi M, et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 2006;281:6120-6123
20. Urakawa I, Yamazaki Y, Shimada T, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006;444:770-774
21. Gattineni J, Bates C, Twombley K, et al. FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. Am J Physiol Renal Physiol 2009: doi: 10.1152/ajprenal.90742. 2008
22. Liu S, Vierthaler L, Tang W, et al. FGFR3 and FGFR4 do not mediate renal effects of FGF23. J Am Soc Nephrol 2008;19:2342-2350
23. Goetz R, Beenken A, Ibrahimi OA, et al. Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol 2007;27:3417-3428
24. Kuro-o M. Klotho as a regulator of fibroblast growth factor signaling and phosphate/calcium metabolism. Curr Opin Nephrol Hypertens 2006;15:437-441
25. Nakatani T, Ohnishi M, Razzaque MS. Inactivation of klotho function induces hyperphosphatemia even in presence of high serum fibroblast growth factor 23 levels in a genetically engineered hypophosphatemic (Hyp) mouse model. Faseb J 2009;23:3702-3711
26. Razzaque MS, Lanske B. The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis. J Endocrinol 2007;194:1-10
27. Razzaque MS. Does FGF23 toxicity influence the outcome of chronic kidney disease? Nephrol Dial Transplant 2009;24:4-7
28. Shimada T, Urakawa I, Isakova T, et al. Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab 2009. doi: 10.1210/jc.2009-1603
29. Lafage-Proust MH. Does the downregulation of the FGF23 signaling pathway in hyperplastic parathyroid glands contribute to refractory secondary hyperparathyroidism in CKD patients? Kidney Int 2010;77:390-392
30. Ohnishi M, Nakatani T, Lanske B, Razzaque MS. In vivo genetic evidence for suppressing vascular and soft tissue calcification through the reduction of serum phosphate levels, even in the presence of high serum calcium and 1,25-dihydroxyvitamin-D levels. Circ Cardiovasc Genet 2009;2:583-590
31. Lanske B, Razzaque MS. Premature aging in klotho mutant mice: cause or consequence? Ageing Res Rev 2007;6:73-79
32. Lanske B, Razzaque MS. Mineral metabolism and aging: the fibroblast growth factor 23 enigma. Curr Opin Nephrol Hypertens 2007;16:311-318
33. Razzaque MS. Can fibroblast growth factor 23 fine-tune therapies for diseases of abnormal mineral ion metabolism? Nat Clin Pract Endocrinol Metab 2007;3:788-789